GlassScriptPhysician profile
Alden Klarer
NPI 1104211341
$2,986.04
in general payments reported to CMS, 2019-2025
36 companies · $892 in 2025
The $892 reported for 2025 was more than what 82% of Radiation Oncology providers received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $376 · 2020: $79.97 · 2021: $63.85 · 2022: $190 · 2023: $410 · 2024: $974 · 2025: $892.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,276.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,276.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $556.58 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Incyte Corporation | $243.53 | 2019-2024 | Jakafi, Monjuvi, Pemazyre |
| Astrazeneca Pharmaceuticals LP | $207.30 | 2021-2025 | Enhertu, Tagrisso |
| Lilly USA, LLC | $190.93 | 2024-2025 | Verzenio, Jaypirca, Retevmo |
| Pfizer INC. | $169.74 | 2024-2025 | |
| Daiichi Sankyo INC. | $162.67 | 2019-2025 | Enhertu, Datroway, Injectafer |
| Stemline Therapeutics INC. | $131.62 | 2023-2024 | Orserdu |
| Genzyme Corporation | $120.80 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $106.29 | 2024-2025 | |
| Gt Medical Technologies, INC | $103.90 | 2022 | |
| Genentech USA, INC. | $81.93 | 2024-2025 | Venclexta, Alecensa, Tecentriq |
| Novocure INC. | $80.68 | 2019-2023 | Optune |
| Abbvie INC. | $80.35 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $79.64 | 2019-2025 | |
| Gilead Sciences, INC. | $72.57 | 2024-2025 | Trodelvy |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $71.16 | 2024-2025 | Orgovyx |
| Janssen Biotech, INC. | $57.41 | 2024-2025 | Rybrevant |
| Celgene Corporation | $52.89 | 2019 | |
| Foundation Medicine, INC. | $43.27 | 2019 | |
| Puma Biotechnology, INC. | $39.92 | 2024-2025 | |
| Clovis Oncology, INC. | $33.71 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $33.31 | 2024 | Iclusig |
| Blueprint Medicines Corporation | $28.51 | 2024 | Ayvakit |
| Monteris Medical Corporation | $25.56 | 2024 | Neuroblate |
| Accuray Incorporated | $22.60 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $22.28 | 2023 | Libtayo |
| Tersera Therapeutics LLC | $20.19 | 2024 | Zoladex |
| Beigene USA, INC. | $18.62 | 2023 | Brukinsa |
| Pharmacosmos Therapeutics INC. | $18.26 | 2023 | Monoferric |
| Karyopharm Therapeutics INC. | $17.24 | 2025 | Xpovio |
| Adc Therapeutics America, INC. | $16.97 | 2023 | |
| Eisai INC. | $16.94 | 2025 | |
| Taiho Oncology, INC. | $15.85 | 2024 | |
| Emd Serono, INC. | $15.50 | 2024 | |
| Jazz Pharmaceuticals INC. | $13.73 | 2019 | |
| Syndax Pharmaceuticals, INC. | $13.59 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alden Klarer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.